BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rizzo A, Brandi G. First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!". Cancer Treat Res Commun 2021;27:100335. [PMID: 33592561 DOI: 10.1016/j.ctarc.2021.100335] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 18.0] [Reference Citation Analysis]
Number Citing Articles
1 Prasopporn S, Suppramote O, Ponvilawan B, Jamyuang C, Chanthercrob J, Chaiboonchoe A, More-krong P, Kongsri K, Suntiparpluacha M, Chanwat R, Korphaisarn K, Okada S, Sampattavanich S, Jirawatnotai S. Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1021632] [Reference Citation Analysis]
2 Brandi G, Rizzo A. IDH Inhibitors and Immunotherapy for Biliary Tract Cancer: A Marriage of Convenience? Int J Mol Sci 2022;23:10869. [PMID: 36142781 DOI: 10.3390/ijms231810869] [Reference Citation Analysis]
3 Rizzo A, Carloni R, Ricci AD, Di Federico A, Guven DC, Yalcin S, Brandi G. Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis. JPM 2022;12:1247. [DOI: 10.3390/jpm12081247] [Reference Citation Analysis]
4 Chen R, Zhang Y, Lin K, Huang D, You M, Lai Y, Wang J, Hu Y, Li N. Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers. Front Pharmacol 2022;13:871262. [DOI: 10.3389/fphar.2022.871262] [Reference Citation Analysis]
5 Rizzo A, Carloni R, Frega G, Palloni A, Di Federico A, Ricci AD, De Luca R, Tavolari S, Brandi G. Intensive Follow-Up Program and Oncological Outcomes of Biliary Tract Cancer Patients after Curative-Intent Surgery: A Twenty-Year Experience in a Single Tertiary Medical Center. Current Oncology 2022;29:5084-5090. [DOI: 10.3390/curroncol29070402] [Reference Citation Analysis]
6 Hosseini Shabanan S, Nezami N, Abdelsalam ME, Sheth RA, Odisio BC, Mahvash A, Habibollahi P. Selective Internal Radiation Therapy with Yttrium-90 for Intrahepatic Cholangiocarcinoma: A Systematic Review on Post-Treatment Dosimetry and Concomitant Chemotherapy. Current Oncology 2022;29:3825-48. [DOI: 10.3390/curroncol29060306] [Reference Citation Analysis]
7 Seeherunwong A, Chaiear N, Khuntikeo N, Ekpanyaskul C. The Proportion of Occupationally Related Cholangiocarcinoma: A Tertiary Hospital Study in Northeastern Thailand. Cancers 2022;14:2386. [DOI: 10.3390/cancers14102386] [Reference Citation Analysis]
8 Haapala I, Kondratev A, Roine A, Mäkelä M, Kontunen A, Karjalainen M, Laakso A, Koroknay-pál P, Nordfors K, Haapasalo H, Oksala N, Vehkaoja A, Haapasalo J. Method for the Intraoperative Detection of IDH Mutation in Gliomas with Differential Mobility Spectrometry. Current Oncology 2022;29:3252-8. [DOI: 10.3390/curroncol29050265] [Reference Citation Analysis]
9 Rizzo A, Cusmai A, Giovannelli F, Acquafredda S, Rinaldi L, Misino A, Palmiotti G. Fluoropyrimidine-based doublet chemotherapy as second-line treatment for advanced biliary tract cancer: a meta-analysis of ABC-06 and NIFTY. Expert Rev Gastroenterol Hepatol 2022;16:273-8. [PMID: 35220866 DOI: 10.1080/17474124.2022.2047651] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Thol F, Gairing SJ, Czauderna C, Thomaidis T, Gamstätter T, Huber Y, Vollmar J, Lorenz J, Michel M, Bartsch F, Müller L, Kloeckner R, Galle PR, Wörns M, Marquardt JU, Moehler M, Weinmann A, Foerster F. Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer. JHEP Reports 2022;4:100417. [DOI: 10.1016/j.jhepr.2021.100417] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Gonzalez-Carmona MA, Möhring C, Mahn R, Zhou T, Bartels A, Sadeghlar F, Bolch M, Vogt A, Kaczmarek DJ, Heling DJ, Dold L, Nattermann J, Branchi V, Matthaei H, Manekeller S, Kalff JC, Strassburg CP, Mohr RU, Weismüller TJ. Impact of regular additional endobiliary radiofrequency ablation on survival of patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy. Sci Rep 2022;12:1011. [PMID: 35046437 DOI: 10.1038/s41598-021-04297-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
12 Rizzo A, Dadduzio V, Lombardi L, Ricci AD, Gadaleta-Caldarola G. Ampullary Carcinoma: An Overview of a Rare Entity and Discussion of Current and Future Therapeutic Challenges. Curr Oncol 2021;28:3393-402. [PMID: 34590592 DOI: 10.3390/curroncol28050293] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 Rizzo A, Ricci AD, Gadaleta-Caldarola G, Brandi G. First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges. Expert Rev Gastroenterol Hepatol 2021;15:1245-51. [PMID: 34431725 DOI: 10.1080/17474124.2021.1973431] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 22.0] [Reference Citation Analysis]
14 Pei SN, Liao CK, Chen YS, Tseng CH, Hung CM, Chiu CC, Hsieh MC, Tsai YF, Liao HY, Liu WC, Rau KM. A Novel Combination of Bevacizumab with Chemotherapy Improves Therapeutic Effects for Advanced Biliary Tract Cancer: A Retrospective, Observational Study. Cancers (Basel) 2021;13:3831. [PMID: 34359732 DOI: 10.3390/cancers13153831] [Reference Citation Analysis]
15 Zou L, Li X, Wu X, Cui J, Cui X, Song X, Ren T, Han X, Zhu Y, Li H, Wu W, Wang X, Gong W, Wang L, Li M, Lau WY, Liu Y. Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study. BMC Cancer 2021;21:818. [PMID: 34266407 DOI: 10.1186/s12885-021-08549-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
16 Ueno M, Morizane C, Okusaka T, Mizusawa J, Kataoka T, Ikeda M, Ozaka M, Okano N, Sugimori K, Todaka A, Shimizu S, Mizuno N, Yamamoto T, Sano K, Tobimatsu K, Katanuma A, Miyamoto A, Yamaguchi H, Nishina T, Shirakawa H, Kojima Y, Oono T, Kawamoto Y, Furukawa M, Iwai T, Sudo K, Miyakawa H, Yamashita T, Yasuda I, Takahashi H, Kato N, Shioji K, Shimizu K, Nakagohri T, Kamata K, Ishii H, Furuse J; members of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG). Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113. Sci Rep 2021;11:12885. [PMID: 34145336 DOI: 10.1038/s41598-021-92166-3] [Reference Citation Analysis]
17 Müller L, Mähringer-Kunz A, Gairing SJ, Foerster F, Weinmann A, Bartsch F, Heuft LK, Baumgart J, Düber C, Hahn F, Kloeckner R. Survival Prediction in Intrahepatic Cholangiocarcinoma: A Proof of Concept Study Using Artificial Intelligence for Risk Assessment. J Clin Med 2021;10:2071. [PMID: 34066001 DOI: 10.3390/jcm10102071] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
18 Rizzo A. Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors. Medicina (Kaunas) 2021;57:458. [PMID: 34066684 DOI: 10.3390/medicina57050458] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
19 Rizzo A, Ricci AD, Brandi G. Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand? Expert Review of Precision Medicine and Drug Development 2021;6:217-24. [DOI: 10.1080/23808993.2021.1915126] [Reference Citation Analysis]